argenx Appoints Steve Krognes to Board of Directors
27 Février 2023 - 10:01PM
GlobeNewswire Inc.
February 27, 2023
Amsterdam, the
Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases, announced that
during the extraordinary general meeting of shareholders held today
at 12:00pm CET, Steve Krognes was appointed as a non-executive
director to its Board of Directors. He will also become the
chairperson of the Audit and Compliance Committee.
As a result of the appointment of Mr. Krognes,
Werner Lanthaler has formally resigned as non-executive director of
the Board of Directors and chairperson of the Audit and Compliance
Committee to enable this important step in long-term succession
planning.
“We welcome Steve to the Board and are confident
that with his strong financial and compliance expertise and
valuable industry knowledge, he possesses the ideal profile to
support argenx on our innovative, entrepreneurial mission,” said
Tim Van Hauwermeiren, Chief Executive Officer of argenx. “I would
also like to express my gratitude to Werner for his substantial
contributions over the last eight years. His entrepreneurial spirit
combined with his broad experience in finance and executive
leadership within biopharma has helped guide us from a research and
development company to a fully integrated, global immunology
company.”
The voting result and all documents relating to
the shareholders’ meeting will be available on the argenx website
at www.argenx.com/investors/shareholder-meetings.
About argenx argenx is a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases. Partnering with
leading academic researchers through its Immunology Innovation
Program (IIP), argenx aims to translate immunology breakthroughs
into a world-class portfolio of novel antibody-based medicines.
argenx developed and is commercializing the first-and-only approved
neonatal Fc receptor (FcRn) blocker in the U.S., the EU and Japan.
For more information, visit www.argenx.com and follow us on
LinkedIn, Twitter, and Instagram.
For further information, please
contact:
Media:Erin
Murphyemurphy@argenx.com
Investors:Beth
DelGiaccobdelgiacco@argenx.com
Argen X (EU:ARGX)
Graphique Historique de l'Action
De Mai 2023 à Juin 2023
Argen X (EU:ARGX)
Graphique Historique de l'Action
De Juin 2022 à Juin 2023